Holen Sie sich die Stockscreener-App
1.63
3.16%
0.05
Schlusskurs vom Vortag:
$1.58
Offen:
$1.59
24-Stunden-Volumen:
7.65M
Relative Volume:
0.96
Marktkapitalisierung:
$492.11M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-1.0867
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-11.41%
1M Leistung:
-26.24%
6M Leistung:
+22.56%
1J Leistung:
-12.83%
1-Tages-Spanne:
$1.54
$1.71
1-Wochen-Bereich:
$1.51
$2.00
52-Wochen-Spanne:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.63 | 477.01M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
113.29 | 195.21B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
377.32 | 141.28B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
98.49 | 123.60B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
76.28 | 113.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.98 | 45.52B | 6.07B | 1.06B | 799.60M | 1.8527 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Pacific Biosciences of California : PACB Q4 2025 Earning Prepared Remarks - marketscreener.com
Exit Recap: Should I invest in Clene Inc before earningsEarnings Risk Summary & Stepwise Swing Trade Plans - baoquankhu1.vn
Pacific Biosciences Faces Turbulent Market Amid Industry Shifts - timothysykes.com
Aug Drivers: Will Pacific Biosciences of California Inc outperform tech stocks2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Is Pacific Biosciences of California Inc. stock a falling knife or bargain buy2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
Will Pacific Biosciences of California Inc. outperform tech stocksJuly 2025 Reactions & High Win Rate Trade Alerts - mfd.ru
How does Pacific Biosciences of California Inc. compare to its peersJuly 2025 Short Interest & Risk Managed Investment Signals - mfd.ru
Pacific Biosciences of California (PACB) reports Q4 loss, beats revenue estimates - MSN
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2025 Earnings Call Transcript - Insider Monkey
Slammed 28% Pacific Biosciences of California, Inc. (NASDAQ:PACB) Screens Well Here But There Might Be A Catch - 富途牛牛
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.8%What's Next? - MarketBeat
Pacific Biosciences of California: Navigating Market Waves Amid Revenue Hurdles - StocksToTrade
PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears - Finviz
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up - TradingView
Pacific Biosciences of California, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
PacBio Q4 2025 slides: Revenue growth and margin expansion driven by human genomics - Investing.com Canada
Pacific Biosciences's Q4 And Full-Year Revenue Improves - Nasdaq
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
Pacific Biosciences of California Inc (PACB) Q4 2025 Earnings Ca - GuruFocus
PacBio (PACB) Q4 2025 Earnings Call Transcript - The Globe and Mail
PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025 - The Globe and Mail
Pacific Biosciences of California Q4 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences of California Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Pacific Biosciences beats Q4 2025 forecasts By Investing.com - Investing.com Canada
PACB: Record consumable growth and SparkNex launch set stage for 8% revenue growth in 2026 - TradingView
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Announces Earnings Results - MarketBeat
Pacific Biosciences: Q4 Earnings Snapshot - kens5.com
PacBio (PACB) Surpasses Q4 Revenue Expectations Amid Strategic E - GuruFocus
PacBio (NASDAQ: PACB) lifts 2025 revenue but posts large restructuring-driven loss - Stock Titan
Pacific Biosciences of California joins iHope to expand genomic sequencing access - Traders Union
PacBio tech joins iHope to help rare disease patients get answers - Stock Titan
Valuation Update: Is Freedom Holding Corp in a bullish channelEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
What analyst consensus says on Pacific Biosciences of California Inc. stockRate Hike & Accurate Technical Buy Alerts - mfd.ru
Pacific Biosciences: Fourth Quarter Earnings Overview - Bitget
How strong is Pacific Biosciences of California Inc. stock revenue growth2025 Stock Rankings & Risk Controlled Stock Alerts - mfd.ru
PacBio Earnings: What To Look For From PACB - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt - 富途牛牛
How The Narrative Around Pacific Biosciences Of California (PACB) Is Shifting As Assumptions Evolve - Yahoo Finance
Buyback Watch: Will BIIB benefit from sector rotationPortfolio Value Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Pacific Biosciences of California (PACB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Risk Recap: Can Pacific Biosciences of California Inc. reach all time highs this yearWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Pacific Biosciences Announces Interim Leadership Role Realignment - The Globe and Mail
Pacific Biosciences showcases automation options at SLAS2026 - Traders Union
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Nigeria
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 7.7%Here's Why - MarketBeat
Pacific Biosciences Sees Strategic Maneuvers Amid Financial Woes - StocksToTrade
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Pacific Biosciences Strengthens Balance Sheet via Asset Sale - TipRanks
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):